These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26604862)

  • 1. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
    Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
    Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Castleman disease.
    Dispenzieri A; Fajgenbaum DC
    Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
    Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
    PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
    Fajgenbaum DC; van Rhee F; Nabel CS
    Blood; 2014 May; 123(19):2924-33. PubMed ID: 24622327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Bertinchamp R; Terriou L
    Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
    Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
    Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
    Fajgenbaum DC
    Blood; 2018 Nov; 132(22):2323-2330. PubMed ID: 30487129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
    Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multicentric Castlemans disease. Symptoms, diagnostics and therapy].
    Adam Z; Řehák Z; Adamová Z; Koukalová R; Pour L; Krejčí M; Boichuk I; Sandecká V; Krejčí M; Štork M; Ševčíková S; Král Z
    Vnitr Lek; 2022; 68(1):41-53. PubMed ID: 35459346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.
    Rodriguez Merino L; Pomares AA; Arce JR; Montes-Moreno S
    J Clin Pathol; 2024 Apr; 77(5):318-323. PubMed ID: 36690434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The full spectrum of Castleman disease: 273 patients studied over 20 years.
    Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L
    Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
    Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
    Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].
    Okamoto S
    Rinsho Ketsueki; 2019; 60(9):1205-1211. PubMed ID: 31597845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.
    Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C
    Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
    Pelliccia S; Rogges E; Cardoni A; Lopez G; Conte E; Faccini AL; De Vito R; Girardi K; Bianchi A; Annibali O; Fratoni S; Remotti D; De Angelis G; Giordano C; Palumbo G; Scarpino S; Del Porto F; Bianchi MP; Di Gregorio F; Tafuri A; Di Napoli A
    Br J Haematol; 2024 Feb; 204(2):534-547. PubMed ID: 37953489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S; Lechowicz MJ; Wong RS; Pierson S; Paessler M; Rossi JF; Ide M; Ruth J; Croglio M; Suarez A; Krymskaya V; Chadburn A; Colleoni G; Nasta S; Jayanthan R; Nabel CS; Casper C; Dispenzieri A; Fosså A; Kelleher D; Kurzrock R; Voorhees P; Dogan A; Yoshizaki K; van Rhee F; Oksenhendler E; Jaffe ES; Elenitoba-Johnson KS; Lim MS
    Blood; 2017 Mar; 129(12):1646-1657. PubMed ID: 28087540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
    Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and management of Castleman disease.
    Soumerai JD; Sohani AR; Abramson JS
    Cancer Control; 2014 Oct; 21(4):266-78. PubMed ID: 25310208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.